Clinical Trial

Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-08.
Status change: Not Yet Recruiting → Recruiting 2025-11-14
Trial Details
NCT Number NCT07115485
Lead Sponsor Shanghai Henlius Biotech
Conditions Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment 60 participants
Start Date 2025-09-15
Primary Completion 2027-08-30 (estimated)
Study Completion 2028-09-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-18